When it comes to screening for colorectal cancer, Mainz Biomed NV (NASDAQ: MYNZ) and Exact Sciences Corp. (NASDAQ: EXAS) have a lot in common. Both are overhauling the screening market for a cancer ...

A new analysis provided “strong” support for starting fecal immunochemical test (FIT) screening at ages 40-49 rather than at the currently recommended age of 50. An exploratory initiative that offered ...